Novartis reports positive trial results for a new multiple sclerosis therapy with reduced liver toxicity
Executive summary: Novartis disclosed positive Phase III results for its new multiple sclerosis medication, demonstrating efficacy and a reduced incidence of liver toxicity. The findings alleviate a major safety issue associated with current MS treatments, potentially improving patient adherence and giving Novartis a differentiated product.
Who is involved: Novartis as the sponsor, clinical investigators, patients with relapsing-remitting MS, and regulators such as the EMA and FDA.
Likely next: Novartis plans to submit the trial data to health authorities for approval, with a possible market launch within 12‑18 months if granted.
Novartis announced that its investigational MS drug met primary efficacy endpoints in a Phase III trial while showing a lower rate of liver-related adverse events compared to existing therapies. The data address a longstanding safety concern that has limited the use of some MS medications. If approved, the drug could strengthen Novartis’s position in the competitive multiple sclerosis market.
Timeline
- — Medizin: Novartis verkündet Studienerfolg von MS-Mittel (Handelsblatt)
Key entities
Sources
- Medizin: Novartis verkündet Studienerfolg von MS-Mittel — Handelsblatt
Related cases
- Henlius and Sandoz partner to co‑develop up to ten biosimilar mAb and ADC assets, aiming to accelerate global market access and revenue generation
- Novartis delivered Q2 2026 sales growth and advanced its drug pipeline while reaffirming its full-year financial guidance
- Novartis reports Q2 sales growth, pipeline advances, and reaffirms full‑year 2026 guidance